Securities Star data center news, blue biological trading closed, closing price 20.52 yuan. The stock rose by the daily limit at 09:37, but did not open the limit. The closing capital was 24.633 million yuan, accounting for 1.15% of its current market value.
In terms of capital flow data, the net inflow of main funds on the same day was 40.8658 million yuan, the net inflow of hot capital was 40.0947 million yuan, and the net outflow of retail funds was 23.2814 million yuan. The flow of funds in the past five days is shown in the following table:
The unit is a hot stock of feed and animal health concepts, with feed concepts up 1.86% and animal health concepts up 0.17% on the day.
The investment logic of the stock is as follows:
1. The main products, feed enzymes, can maximize the utilization rate of feed for animals and improve food safety while bringing animal health. Microecological preparation products have been used in feed, agriculture and other fields; at present, the company has formed two major databases: feed enzyme precision application database and animal microecological anti-antibody application database, which make continuous innovation reserve for the continuous upgrading and iteration of anti-product scheme.
2. High-quality enterprises in the animal protection industry, with the only national animal health products engineering and technology research center in the animal health products industry, ranking among the top five in the animal protection industry in the total number of new veterinary drugs registered in the past decade, 69 invention patents related to animal health products, 1 patent authorized by the United States, 2 PCT international applications, and 36 national new veterinary drug certificates. Aiming at classical swine fever, pseudorabies and other vaccines to upgrade the process, significantly enhance the competitiveness of the product market; in 19 years, the related business income was 286 million yuan, accounting for 33.77% of the main business.
In terms of financial situation, Azure Bio 2021 reported that the company's main income was 549 million yuan, up 27.27% from the same period last year; net profit from its mother was 61.341 million yuan, up 39.54% from the same period last year; deducting 47.8456 million yuan from non-net profit, up 34.93% from the same period last year; debt ratio 14.57%, investment income 2.3883 million yuan, financial expenses 1.6839 million yuan, gross profit margin 46.4%.
The Securities Star valuation analysis tool shows that the stock has a good company rating of 3 stars, a good price rating of 3 stars, and a comprehensive valuation rating of 3 stars.
Disclaimer: the relevant content according to the public big data analysis, does not constitute investment advice, the stock market is risky, investment should be cautious.